Kick-starting the cancer-immunity cycle by targeting CD40

Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellmark, P, Mangsbo, S M, Furebring, C, Tötterman, T H, Norlén, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485842/
https://www.ncbi.nlm.nih.gov/pubmed/26140231
http://dx.doi.org/10.1080/2162402X.2015.1011484
_version_ 1782378821682462720
author Ellmark, P
Mangsbo, S M
Furebring, C
Tötterman, T H
Norlén, P
author_facet Ellmark, P
Mangsbo, S M
Furebring, C
Tötterman, T H
Norlén, P
author_sort Ellmark, P
collection PubMed
description Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.
format Online
Article
Text
id pubmed-4485842
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-44858422016-02-03 Kick-starting the cancer-immunity cycle by targeting CD40 Ellmark, P Mangsbo, S M Furebring, C Tötterman, T H Norlén, P Oncoimmunology Author's View Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens. Taylor & Francis 2015-03-16 /pmc/articles/PMC4485842/ /pubmed/26140231 http://dx.doi.org/10.1080/2162402X.2015.1011484 Text en © 2015 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Ellmark, P
Mangsbo, S M
Furebring, C
Tötterman, T H
Norlén, P
Kick-starting the cancer-immunity cycle by targeting CD40
title Kick-starting the cancer-immunity cycle by targeting CD40
title_full Kick-starting the cancer-immunity cycle by targeting CD40
title_fullStr Kick-starting the cancer-immunity cycle by targeting CD40
title_full_unstemmed Kick-starting the cancer-immunity cycle by targeting CD40
title_short Kick-starting the cancer-immunity cycle by targeting CD40
title_sort kick-starting the cancer-immunity cycle by targeting cd40
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485842/
https://www.ncbi.nlm.nih.gov/pubmed/26140231
http://dx.doi.org/10.1080/2162402X.2015.1011484
work_keys_str_mv AT ellmarkp kickstartingthecancerimmunitycyclebytargetingcd40
AT mangsbosm kickstartingthecancerimmunitycyclebytargetingcd40
AT furebringc kickstartingthecancerimmunitycyclebytargetingcd40
AT tottermanth kickstartingthecancerimmunitycyclebytargetingcd40
AT norlenp kickstartingthecancerimmunitycyclebytargetingcd40

Ejemplares similares